Weight gain associated with the α2a-adrenergic receptor -1291 C/G polymorphism and olanzapine treatment

Young Min Park, Young Cho Chung, Seung Hwan Lee, Kang Joon Lee, Hyun Kim, Young Chan Byun, Se Won Lim, Jong Woo Paik, Heon-Jeong Lee

Research output: Contribution to journalArticle

67 Citations (Scopus)

Abstract

Weight gain can be an adverse effect of antipsychotics and is an important factor for long-term health and treatment compliance. Many reports have shown that the α2-adrenergic receptor may be related to eating behaviors or lipolytic activities, both associated with body weight change. We hypothesized that there might be a relationship between the α 2a-adrenergic receptor -1291 C/G polymorphism and olanzapine-induced weight gain. A group of 62 Korean schizophrenic patients participated in a study; weight and height measurements were obtained prior to starting olanzapine and measured again after long-term treatment. Genotyping for the -1291 C/G polymorphism was performed on all participants. Body weight changes from baseline to endpoint were significantly associated with genotypes (P = 0.028). The frequency of the G allele was significantly higher in subjects who had severe weight gain (defined as a more than 10% weight gain from baseline) compared to subjects who did not have extreme weight gain (less than 10% weight gain from baseline) (X2 = 6.120, P = 0.013; OR = 2.58, 95% CI = 1.21-5.51). Therefore, the findings from this study support a relationship between the -1291 C/G polymorphism of the α2a-adrenergic receptor and weight gain in Korean schizophrenic patients receiving olanzapine treatment.

Original languageEnglish
Pages (from-to)394-397
Number of pages4
JournalAmerican Journal of Medical Genetics, Part B: Neuropsychiatric Genetics
Volume141
Issue number4
DOIs
Publication statusPublished - 2006 Jun 5

Fingerprint

olanzapine
Adrenergic Receptors
Weight Gain
Body Weight Changes
Therapeutics
Feeding Behavior
Gene Frequency
Antipsychotic Agents
Genotype

Keywords

  • α-adrenergic receptor
  • Olanzapine
  • Polymorphisms
  • Schizophrenia
  • Weight gain

ASJC Scopus subject areas

  • Genetics(clinical)
  • Neuropsychology and Physiological Psychology
  • Neuroscience(all)

Cite this

Weight gain associated with the α2a-adrenergic receptor -1291 C/G polymorphism and olanzapine treatment. / Park, Young Min; Chung, Young Cho; Lee, Seung Hwan; Lee, Kang Joon; Kim, Hyun; Byun, Young Chan; Lim, Se Won; Paik, Jong Woo; Lee, Heon-Jeong.

In: American Journal of Medical Genetics, Part B: Neuropsychiatric Genetics, Vol. 141, No. 4, 05.06.2006, p. 394-397.

Research output: Contribution to journalArticle

Park, Young Min ; Chung, Young Cho ; Lee, Seung Hwan ; Lee, Kang Joon ; Kim, Hyun ; Byun, Young Chan ; Lim, Se Won ; Paik, Jong Woo ; Lee, Heon-Jeong. / Weight gain associated with the α2a-adrenergic receptor -1291 C/G polymorphism and olanzapine treatment. In: American Journal of Medical Genetics, Part B: Neuropsychiatric Genetics. 2006 ; Vol. 141, No. 4. pp. 394-397.
@article{e72c71df4a09422289e1e3ad4056b767,
title = "Weight gain associated with the α2a-adrenergic receptor -1291 C/G polymorphism and olanzapine treatment",
abstract = "Weight gain can be an adverse effect of antipsychotics and is an important factor for long-term health and treatment compliance. Many reports have shown that the α2-adrenergic receptor may be related to eating behaviors or lipolytic activities, both associated with body weight change. We hypothesized that there might be a relationship between the α 2a-adrenergic receptor -1291 C/G polymorphism and olanzapine-induced weight gain. A group of 62 Korean schizophrenic patients participated in a study; weight and height measurements were obtained prior to starting olanzapine and measured again after long-term treatment. Genotyping for the -1291 C/G polymorphism was performed on all participants. Body weight changes from baseline to endpoint were significantly associated with genotypes (P = 0.028). The frequency of the G allele was significantly higher in subjects who had severe weight gain (defined as a more than 10{\%} weight gain from baseline) compared to subjects who did not have extreme weight gain (less than 10{\%} weight gain from baseline) (X2 = 6.120, P = 0.013; OR = 2.58, 95{\%} CI = 1.21-5.51). Therefore, the findings from this study support a relationship between the -1291 C/G polymorphism of the α2a-adrenergic receptor and weight gain in Korean schizophrenic patients receiving olanzapine treatment.",
keywords = "α-adrenergic receptor, Olanzapine, Polymorphisms, Schizophrenia, Weight gain",
author = "Park, {Young Min} and Chung, {Young Cho} and Lee, {Seung Hwan} and Lee, {Kang Joon} and Hyun Kim and Byun, {Young Chan} and Lim, {Se Won} and Paik, {Jong Woo} and Heon-Jeong Lee",
year = "2006",
month = "6",
day = "5",
doi = "10.1002/ajmg.b.30311",
language = "English",
volume = "141",
pages = "394--397",
journal = "American Journal of Medical Genetics, Part B: Neuropsychiatric Genetics",
issn = "1552-4841",
publisher = "Wiley-Liss Inc.",
number = "4",

}

TY - JOUR

T1 - Weight gain associated with the α2a-adrenergic receptor -1291 C/G polymorphism and olanzapine treatment

AU - Park, Young Min

AU - Chung, Young Cho

AU - Lee, Seung Hwan

AU - Lee, Kang Joon

AU - Kim, Hyun

AU - Byun, Young Chan

AU - Lim, Se Won

AU - Paik, Jong Woo

AU - Lee, Heon-Jeong

PY - 2006/6/5

Y1 - 2006/6/5

N2 - Weight gain can be an adverse effect of antipsychotics and is an important factor for long-term health and treatment compliance. Many reports have shown that the α2-adrenergic receptor may be related to eating behaviors or lipolytic activities, both associated with body weight change. We hypothesized that there might be a relationship between the α 2a-adrenergic receptor -1291 C/G polymorphism and olanzapine-induced weight gain. A group of 62 Korean schizophrenic patients participated in a study; weight and height measurements were obtained prior to starting olanzapine and measured again after long-term treatment. Genotyping for the -1291 C/G polymorphism was performed on all participants. Body weight changes from baseline to endpoint were significantly associated with genotypes (P = 0.028). The frequency of the G allele was significantly higher in subjects who had severe weight gain (defined as a more than 10% weight gain from baseline) compared to subjects who did not have extreme weight gain (less than 10% weight gain from baseline) (X2 = 6.120, P = 0.013; OR = 2.58, 95% CI = 1.21-5.51). Therefore, the findings from this study support a relationship between the -1291 C/G polymorphism of the α2a-adrenergic receptor and weight gain in Korean schizophrenic patients receiving olanzapine treatment.

AB - Weight gain can be an adverse effect of antipsychotics and is an important factor for long-term health and treatment compliance. Many reports have shown that the α2-adrenergic receptor may be related to eating behaviors or lipolytic activities, both associated with body weight change. We hypothesized that there might be a relationship between the α 2a-adrenergic receptor -1291 C/G polymorphism and olanzapine-induced weight gain. A group of 62 Korean schizophrenic patients participated in a study; weight and height measurements were obtained prior to starting olanzapine and measured again after long-term treatment. Genotyping for the -1291 C/G polymorphism was performed on all participants. Body weight changes from baseline to endpoint were significantly associated with genotypes (P = 0.028). The frequency of the G allele was significantly higher in subjects who had severe weight gain (defined as a more than 10% weight gain from baseline) compared to subjects who did not have extreme weight gain (less than 10% weight gain from baseline) (X2 = 6.120, P = 0.013; OR = 2.58, 95% CI = 1.21-5.51). Therefore, the findings from this study support a relationship between the -1291 C/G polymorphism of the α2a-adrenergic receptor and weight gain in Korean schizophrenic patients receiving olanzapine treatment.

KW - α-adrenergic receptor

KW - Olanzapine

KW - Polymorphisms

KW - Schizophrenia

KW - Weight gain

UR - http://www.scopus.com/inward/record.url?scp=33745013199&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=33745013199&partnerID=8YFLogxK

U2 - 10.1002/ajmg.b.30311

DO - 10.1002/ajmg.b.30311

M3 - Article

VL - 141

SP - 394

EP - 397

JO - American Journal of Medical Genetics, Part B: Neuropsychiatric Genetics

JF - American Journal of Medical Genetics, Part B: Neuropsychiatric Genetics

SN - 1552-4841

IS - 4

ER -